ID 445472667 · FY 2017–2024 · 8 years
Georgian subsidiary of the German Aliud Pharma / Unitas group, distributing generic pharmaceuticals.
curated 2026-06-03reportal.ge
| Line item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 13,367 | 36,601 | 1,798 | 1 | 38,269 | 58,223 | 76,750 | +33.8% |
| Total COGS | 0 | -7,459 | -13,734 | -3,096 | -380 | -17,055 | -25,944 | -28,137 | +24.8% |
| Gross Profit | 0 | 5,908 | 22,866 | -1,298 | -379 | 21,214 | 32,279 | 48,613 | +42.1% |
| Gross Margin | 0.0% | 44.2% | 62.5% | -72.2% | -30734.0% | 55.4% | 55.4% | 63.3% | |
| Total Operating Expenses | -255 | -10,887 | -22,325 | -5,522 | -755 | -16,249 | -24,993 | -32,898 | nmf |
| EBITDA | -255 | -4,980 | 541 | -6,821 | -1,134 | 4,965 | 7,286 | 15,715 | nmf |
| EBITDA Margin | 0.0% | -37.3% | 1.5% | -379.3% | -91968.6% | 13.0% | 12.5% | 20.5% | |
| Total D&A | -8 | -4,499 | -7,581 | -7,998 | -7,820 | -7,130 | -7,027 | -7,137 | nmf |
| EBIT / Operating Income | -263 | -9,479 | -7,040 | -14,818 | -8,953 | -2,165 | 259 | 8,577 | nmf |
| Total Interest Income | 44 | 824 | 1,157 | 2,105 | 11,257 | 0 | 0 | 0 | nmf |
| Total Interest Expense | -495 | -4,140 | -4,965 | -5,950 | -6,902 | -4,292 | -4,815 | -4,582 | +37.4% |
| Total Other Income | -2,124 | -3,225 | -5,584 | -16,411 | 0 | 17,956 | -271 | -3,527 | +7.5% |
| Profit Before Tax | -2,840 | -16,019 | -16,432 | -35,076 | -4,599 | 11,498 | -4,827 | 469 | nmf |
| Total Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net Profit / (Loss) | -2,969 | -17,260 | -18,232 | -36,424 | -6,046 | 6,405 | -4,827 | 469 | nmf |
| Net Margin | 0.0% | -129.1% | -49.8% | -2025.6% | -490383.2% | 16.7% | -8.3% | 0.6% |
Ownership & directors from companyinfo.ge (public corporate registry).